ASXL1 and chronic myelogenous leukemia, BCR-ABL1 positive: ASXL1 was the most frequently mutated gene, and subjects with this mutation were less likely to achieve MR4.0 at 36 months, suggesting a reduced sensitivity to TKIs in CML patients with ASXL1.